Biotech InxMed will continue to build a distinct translational medicine platform rooted in disease biology and technological breakthroughs with the fresh proceeds.
InxMed (Chinese: 应世生物) recently announced that it completed a new financing round worth tens of millions of USD from SPD Silicon Valley Bank (Chinese: 浦发硅谷银行).
Founded in 2018, InxMed, a clinical-stage global biotech，focuses on the research and development for innovative drugs in a tumor fibrosis micro-environment. It amis to find solutions for oncology drug resistance and tumor metastasis, especially resistance to anti-PD-1. The company is dedicated to building a distinct translational medicine platform with strong proof-of-concept validation capability.
IN10018, FAK inhibitor, the fastest growing innovative drug program of the company, is currently under investigation for the IND application in China and the United States for multiple cancer types with different combination regimens. IN10018 received Fast-track Designation from the US Food and Drug Administration in August 2021 and Breakthrough Therapy Designation from China National Medical Products Administration in April 2022. InxMed has also reached multiple partnerships with well-known multinational pharmaceutical companies including Roche (Chinese: 罗氏制药), Boehringer Ingelheim (Chinese: 勃林格殷格翰), and MSD (Chinese: 默沙东).
InxMed's competitors include Elpiscience (Chinese: 科望生物), LaNova (Chinese: 礼新医药) and Immunophage (Chinese: 艾美斐生物医药).